An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus

…, S Hamilton, GY Krippner, B Lin, A Luttick…

文献索引：Feil, Susanne C.; Hamilton, Stephanie; Krippner, Guy Y.; Lin, Bo; Luttick, Angela; McConnell, Darryl B.; Nearn, Roland; Parker, Michael W.; Ryan, Jane; Stanislawski, Pauline C.; Tucker, Simon P.; Watson, Keith G.; Morton, Craig J. ACS Medicinal Chemistry Letters, 2012 , vol. 3, # 4 p. 303 - 307

全文：HTML全文

被引用次数: 17

摘要

Respiratory infections caused by human rhinovirus are responsible for severe exacerbations of underlying clinical conditions such as asthma in addition to their economic cost in terms of lost working days due to illness. While several antiviral compounds for treating rhinoviral infections have been discovered, none have succeeded, to date, in reaching approval for clinical use. We have developed a potent, orally available rhinovirus inhibitor 6 that has ...